Clearmind Medicine Inc.
corporate_fare Company Profile
Clearmind Medicine Inc. (NASDAQ:CMND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 78 items for CMND at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above. Recent SEC coverage for CMND spans 6-K.
Recent high-impact activity:
- Clearmind Draws $2M Convertible Notes at 10% Discount Under Existing $10M Facility
- Clearmind Medicine Sets 1-for-8 Reverse Split for October 5
- Clearmind Medicine enrolls first Alcohol Use Disorder patients in CMND-100 clinical trial
- Clearmind Doses First Alcohol Use Disorder Patients in CMND-100 Trial
- Clearmind Closes $2.5M Charging Robotics Acquisition, Adds $1.5M Loan
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 3,861 shares in CMND as of the October 15, 2026 settlement, a 73.9% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 30, 2026, 64.8% of CMND volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CMND, detected from its recent SEC filings · based on capital-structure filings through 2026-06-15.
Going Concern Warning Issued · Significant Capital Raise and Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
CMND files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.